Vol 2, No 2 (2014)

The article presents the results of the research of morphology and porous structure of medical clays. The specific surface area, volume of pores and the average size of pores were identified.

Among the contemporary medicinal remedies the derivatives of g - aminobutyric acid have a special place. The present work is devoted to the remedy «Aminalon» which has a dignity of a combination of nootropic and neuroprotective actions and it has special value for the geriatric and pediatric practices. The task of the authors was a holding of a market review with the purpose to generalize the information about the place of the given remedy as a segment of the pharmaceutical market.

Bay laurel (Laurus nobilis L.) is common in the Mediterranean region, Europe and America. Widely cultivated in the countries of the Arabian Peninsula and North Africa. As the basic active substances in plants: essential oil components, sesquiterpene lactones, alkaloids, and phenolic compounds (flavonoids, phenolic acids and lignans) are described. In the plant more than 30 sesquiterpene lactones are found. Structural types of these compounds include eudesmanolides, germacranolides, guaianolides. Sesquiterpene lactones isolated from the leaves and fruits of Laurus nobilis, possess antibacterial, antifungal, anti-diabetic, anti-inflammatory, hepatoprotective, neuroprotective and cytotoxic activity. They inhibit the absorption of alcohol increases the activity of hepatic glutathione-S-transferase. Most of these types of activity of sesquiterpene lactones from laurel due to the presence within their structure of α-methylene-g-butyrolactone part. Thus, sesquiterpene lactones-containing leaves and fruits Laurus nobilis could have been an important source of raw materials for the creation of new medicines.

The results of development of the immunomodulator timotsin based on coordination compounds dipeptide isoleucyl-tryptophan with zinc, including the synthesis of low molecular weight peptides by immunoactive activated esters, determination regarding the immunostimulatory activity of thymosin α1, study of coordination of dipeptide isoleucyl-tryptophan with zinc, study the immunostimulatory activity of coordination compounds, the results of preclinical and clinical studies of timotsin. pH-metric method and red-ox titration showed that the interaction of zinc and of dipeptide isoleucyl-tryptophan formed in solution following complex forms: [ZnHL] (lgæ = 3,71), Zn(HL) 2 (lgβ = 0,279), ZnL(HL) (lgβ = 6,6), Zn 2(HL) 2 (lgβ = 188), Zn(OH)(HL) (lgβ = -0,256). It was shown that the immunostimulatory activity of coordination compounds is in 2-8 times greater than the starting dipeptide. The developed immunomodulatory drug timotsin showed high therapeutic efficacy in the treatment of viral hepatitis, malignant tumors of different localization, psoriasis and neurodermatitis. Timotsin is registered in Tajikistan (registration number of medical drug №000085T), Kyrgyzstan (medical drug №7137) and Turkmenistan (registration number 006371).

Results of the development of an immunomodulating drug timofer based on coordination compounds isoleucyl-tryptophan dipeptide with iron (II), including the study of coordinate isoleucyl-tryptophan dipeptide with iron (II), the study of the immunostimulatory activity of the coordination compounds, the results of the preclinical and clinical studies of timotsin are presented. Method of pH titration showed that the interaction of zinc and dipeptide isoleucyl-tryptophan formed in solution following complex forms: [Fe (HL ±)] 2+ (β = 1,00×10 34), [Fe (HL ±) 2] 2+ (β = 6,25×10 11), [Fe (HL ±)OH] + (β = 4,01×10 26), [Fe (L -)] + (β = 8,10×10 18), [Fe (L -) 2] + (β = 7,50×10 28), [Fe (L -)OH] + (β = 1,03×10 29). It was shown that the immunostimulatory activity of the coordination compounds is 2 times higher than that starting dipeptide. The substance sample and standard formulation of timofer were developed and standardized. The developed immunomodulatory drug timofer showed a high therapeutic efficacy in the treatment of iron deficiency anemia patients with inflammatory processes and traumatic injuries of the maxillofacial region, with chronic inflammatory diseases of the the genitals (CMV, HSV, chlamydia, chronic endometritis, chronic salpingoopharitis, ureaplasmosis) with chronic bronchitis, chronic obstructive bronchitis, bronchial asthma, pneumonia, chronic glomerulonephritis, and chronic renal failure complicated by anemia Bright, withrheumatic diseases, gynecological patients with anemia of moderate and severe degrees of severity, at surgical treatment of patients with suppurative lung disease, heart disease and chronic pericarditis operated with cardiopulmonary bypass. Timofer is registered in Tajikistan (registration number of medical drug №002866).